FDA Determines Regulatory Review Period for IONSYS Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for IONSYS, a pharmaceutical company, in relation to a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO). The FDA is publishing this notice as required by law, following the submission of an application for the extension of a patent claiming a human drug product.